Clemens Schulte

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht et al. · The Lancet Oncology · 2024 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy

Anna Kron, Matthias Scheffler, Carina Heydt et al. · Journal of Thoracic Oncology · 2020 · 69 citations · Full text

Medicine, Genetics, Oncology +14

Molecular characterization of AIFM2/FSP1 inhibition by iFSP1-like molecules

Thamara Nishida Xavier da Silva, Clemens Schulte, Ariane Nunes‐Alves et al. · Cell Death and Disease · 2023 · 57 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

<i>In Vitro</i> Blood–Brain Barrier Permeability and Cytotoxicity of an Atorvastatin-Loaded Nanoformulation Against Glioblastoma in 2D and 3D Models

Michael M. Lübtow, Sabrina Oerter, Sabina Quader et al. · Molecular Pharmaceutics · 2020 · 43 citations · Full text

Pharmacy, Oncology, Pharmacology +17